Product image of Melfalan Eugia (Melphalan) supplied by GNH India

Melfalan Eugia

Active Ingredient:
Melphalan
Origin:
EU

Melfalan Eugia (Melphalan)

Melphalan, the active ingredient in Melfalan Eugia, is an alkylating agent presented as an intravenous formulation for oncology use. It is employed in the treatment of several hematologic and solid‑tumor cancers, acting by interfering with DNA replication in malignant cells.

GNH India supplies Melfalan Eugia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Manufacturer / TM Owner

Eugia Pharma (Malta) Ltd

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Melfalan Eugia is an alkylating antineoplastic used in the management of malignancies that rely on DNA synthesis pathways.

  • Multiple myeloma: helps achieve disease control and prolong survival in eligible patients.
  • Ovarian cancer: used as part of combination regimens to reduce tumor burden.
  • Malignant melanoma: employed in selected cases to inhibit tumor growth.
  • Chronic lymphocytic leukemia: contributes to remission when combined with other therapies.

How It Works

  • Melphalan alkylates nucleophilic sites on DNA, forming intra‑ and interstrand cross‑links that block DNA replication and transcription. The resulting DNA damage triggers cell‑cycle arrest and apoptosis, preferentially affecting rapidly dividing malignant cells while sparing most normal tissues.

Side Effects

Melfalan Eugia may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

  • Nausea and vomiting: gastrointestinal upset commonly reported during treatment.
  • Alopecia: reversible hair loss affecting scalp and body hair.
  • Myelosuppression: decreased blood cell counts leading to anemia, neutropenia, or thrombocytopenia.
  • Fatigue: generalized tiredness often accompanying cytopenias.
  • Mucositis: inflammation of the oral and gastrointestinal mucosa.

Serious or Rare Side Effects

  • Severe infection: due to profound neutropenia, requiring prompt medical attention.
  • Secondary malignancies: rare development of new cancers after prolonged exposure.
  • Renal toxicity: impaired kidney function in susceptible individuals.
  • Pulmonary fibrosis: uncommon lung scarring with chronic use.
  • Cardiotoxicity: rare cardiac dysfunction observed in high‑dose regimens.

Precautions & Warnings

Before initiating therapy with Melfalan Eugia, several safety considerations should be observed.

  • Baseline blood counts: obtain complete blood count to assess marrow reserve.
  • Renal function monitoring: evaluate serum creatinine and adjust dosing if needed.
  • Pregnancy avoidance: advise women of childbearing potential to use effective contraception.
  • Concomitant myelosuppressive agents: avoid combining with other drugs that depress bone marrow.
  • Live vaccines: contraindicated during treatment due to immunosuppression.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Melfalan Eugia can interact with other medicines, influencing efficacy or toxicity.

Major Interactions (Avoid)

  • Other alkylating agents: additive bone‑marrow suppression.
  • High‑dose radiation therapy: increased risk of severe tissue injury.
  • Myelosuppressive antibiotics (e.g., chloramphenicol): heightened cytopenia.

Moderate Interactions (Monitor Closely)

  • Nephrotoxic drugs (e.g., cisplatin): may exacerbate renal impairment.
  • Anticoagulants (e.g., warfarin): monitor coagulation parameters.
  • CYP450 inducers/inhibitors: may alter melphalan clearance, requiring dose adjustment.

Frequently Asked Questions

Melfalan Eugia contains melphalan, an alkylating chemotherapy agent indicated for multiple myeloma, ovarian cancer, malignant melanoma, and chronic lymphocytic leukemia. It is used as part of approved treatment protocols to reduce tumor burden and improve disease outcomes in these malignancies.

Melphalan exerts its antineoplastic effect by alkylating DNA bases, creating cross‑links that prevent DNA replication and transcription. This DNA damage triggers cell‑cycle arrest and apoptosis, preferentially targeting rapidly dividing cancer cells while sparing most normal tissues.

The specific dose of Melfalan Eugia is determined by the prescribing oncologist based on the patient’s diagnosis, disease stage, body surface area, renal function, and prior therapies. Only a qualified healthcare professional should set the dosing regimen.

Melphalan is classified as contraindicated in pregnancy because it can cause fetal harm. Women of childbearing potential should use effective contraception during treatment and for a period afterward. Breastfeeding is not recommended while receiving melphalan, as the drug may be excreted in milk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Melfalan Eugia (melphalan) is a nitrogen mustard derivative similar to cyclophosphamide but is more lipophilic, allowing better tissue penetration. It is often chosen for specific indications such as multiple myeloma and ovarian cancer where clinical data support its efficacy, whereas other alkylators may be preferred for different tumor types or toxicity profiles.

Melfalan Eugia should be stored at 2‑8 °C in a refrigerator, protected from light, and kept in its original packaging. Do not freeze or shake the product, and ensure it is handled according to cold‑chain requirements to maintain stability.

Melfalan Eugia is supplied for intravenous infusion. The drug is reconstituted according to the manufacturer’s instructions and administered by a qualified healthcare professional, typically over a defined period under close monitoring for infusion‑related reactions and hematologic effects.

The most serious risks include severe myelosuppression leading to infection, anemia or bleeding; secondary malignancies such as therapy‑related leukemia; renal toxicity; and rare pulmonary fibrosis. Patients should be monitored closely for signs of infection, blood count changes, and organ dysfunction throughout therapy.

Melfalan Eugia is contraindicated in patients with known hypersensitivity to melphalan or other alkylating agents, those with severe bone‑marrow failure, uncontrolled infections, or significant renal impairment. It should also be avoided in pregnant women and in individuals receiving live vaccines during treatment.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Melphalan

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT